Complete remission of VZV reactivation treated with valganciclovir in a patient with total lymphocyte depletion and acute kidney injury after allogeneic bone marrow transplantation

Natalia Maximova, Pizzol Antonio, Granzotto Marilena, Francesca Rovere, Paolo Tamaro

Research output: Contribution to journalArticlepeer-review

Abstract

Varicella zoster virus (VZV), a threat for hematopoietic stem cell transplantation (HSCT) recipients, is still one of the most common viral pathogens that affect these patients with a reported incidence ranging between 17% and 50% in the post transplantation period. Valganciclovir (V-GCV), a valine ester pro-drug of GCV orally administrable, has recently shown great activity against CMV infections, but there are no reports of its clinical efficacy against VZV. We here report a case history of a patient with positive serologic test for VZV, who underwent allogeneic HSCT and developed an atypical varicella-like illness. First-line therapy with foscarnet had to be discontinued due rapid development of renal impairment (creatinine: 2.60 mg/dL, urea: 130.6 mg/dL) and therefore was switched to V-GCV. The renal impairment and skin lesions of the patient fully recovered after few days of therapy, even though the patient had complete lymphocyte depletion. This is the first case of a patient with chickenpox-like illness treated successfully with V-GCV.

Original languageEnglish
Pages (from-to)77-80
Number of pages4
JournalAPMIS
Volume123
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Keywords

  • HSCT
  • Lymphocyte depletion
  • Valganciclovir
  • VZV

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Microbiology (medical)
  • Immunology and Allergy
  • Medicine(all)

Fingerprint Dive into the research topics of 'Complete remission of VZV reactivation treated with valganciclovir in a patient with total lymphocyte depletion and acute kidney injury after allogeneic bone marrow transplantation'. Together they form a unique fingerprint.

Cite this